Back to Search
Start Over
Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy
- Source :
- International journal of clinical oncology. 16(2)
- Publication Year :
- 2010
-
Abstract
- In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated.Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 μg) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 μg) was administered every other day to the other half of the patients when leukocytopenia (1.5 × 10(9)/L) and/or neutropenia (0.5 × 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed.No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF.We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.
- Subjects :
- Male
medicine.medical_specialty
Neutropenia
Fever
Neutrophils
medicine.medical_treatment
Cost-Benefit Analysis
Granulocyte
Drug Administration Schedule
Lenograstim
Surgical oncology
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Granulocyte Colony-Stimulating Factor
medicine
Leukocytes
Humans
In patient
Intensive care medicine
Cyclophosphamide
Aged
Chemotherapy
Antibiotics, Antineoplastic
business.industry
Hematology
General Medicine
Middle Aged
medicine.disease
Chemotherapy regimen
Recombinant Proteins
Granulocyte colony-stimulating factor
medicine.anatomical_structure
Oncology
Doxorubicin
Vincristine
Prednisone
Surgery
Female
Cost benefit
Lymphoma, Large B-Cell, Diffuse
business
Febrile neutropenia
Subjects
Details
- ISSN :
- 14377772
- Volume :
- 16
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- International journal of clinical oncology
- Accession number :
- edsair.doi.dedup.....0ec238e704f570ba0bfe566b195b78d2